Hur är det att dö i prostatacancer?
Dödligheten i prostatacancer 2020 var 149 dödsfall per 100 000 män med förgymnasial utbildningsnivå, 51 dödsfall per 100 000 män med gymnasial utbildningsnivå och 34 dödsfall per 100 000 män med eftergymnasial utbildningsnivå (figur 2).
Totalt avled 2 243 män i prostatacancer 2020, vilket motsvarar 53 dödsfall per 100 000 män (figur 1). Dödligheten ökar tydligt med stigande ålder. Bland män 85 år och äldre var det 973 dödsfall per 100 000, bland män 65–84 år var det 142 per 100 000 och bland män 45–64 år var det 6,3 dödsfall per 100 000 (figur 1).
What is the CyberKnife System?
The CyberKnife System is a radiation therapy device manufactured by Accuray Incorporated. The system is used to deliver radiosurgery for the treatment of benign tumors, malignant tumors and other medical conditions.
What is a Cyberknife M6?
A CyberKnife M6 System at the European CyberKnife Center Munich-Großhadern, Germany. The CyberKnife System is a radiation therapy device manufactured by Accuray Incorporated. The system is used to deliver radiosurgery for the treatment of benign tumors, malignant tumors and other medical conditions.
What is CyberKnife radiotherapy?
The CyberKnife System is designed to deliver radiotherapy more accurately than standard radiotherapy devices. The system was invented by John R. Adler, a Stanford University professor of neurosurgery and radiation oncology, and Peter and Russell Schonberg of Schonberg Research Corporation.
When was CyberKnife approved by the FDA?
Cyberknife. The first system was installed at Stanford University in 1991 and was cleared by the FDA for clinical investigation in 1994. After years of clinical investigation the FDA cleared the system for the treatment of intracranial tumors in 1999 and for the treatment of tumors anywhere in the body in 2001.